Sporothrix schenckii and Sporotrichosis

LEILA M. LOPES-BEZERRA1, ARMANDO SCHUBACH2 and ROSANE O. COSTA3

1Universidade do Estado do Rio de Janeiro/UERJ
Instituto de Biologia Roberto Alcantara Gomes, Departamento de Biologia Celular e Genética
Rua São Francisco Xavier, 524 PHLC, sl. 205, Maracanã
20550-013 Rio de Janeiro, RJ, Brasil
2Instituto Oswaldo Cruz, Instituto de Pesquisa Clínica Evandro Chagas
Departamento de Doenças Infecciosas, Av. Brasil 4365, Manguinhos
21040-900 Rio de Janeiro, RJ, Brasil
3Universidade do Estado do Rio de Janeiro/UERJ, Hospital Universitário Pedro Ernesto
Av. 28 de Setembro 77, Vila Isabel, 20551-900 Rio de Janeiro, RJ, Brasil

Manuscript received on September 26, 2005; accepted for publication on October 10, 2006
presented by LUIZ R. TRAVASSOS

ABSTRACT

For a long time sporotrichosis has been regarded to have a low incidence in Brazil; however, recent studies demonstrate that not only the number of reported cases but also the incidence of more severe or atypical clinical forms of the disease are increasing. Recent data indicate that these more severe forms occur in about 10% of patients with confirmed diagnosis. The less frequent forms, mainly osteoarticular sporotrichosis, might be associated both with patient immunodepression and zoonotic transmission of the disease. The extracutaneous form and the atypical forms are a challenge to a newly developed serological test, introduced as an auxiliary tool for the diagnosis of unusual clinical forms of sporotrichosis.

Key words: sporotrichosis, diagnosis, epidemiology, drugs, cell wall, antigens.

Sporothrix schenckii

Sporotrichosis was described for the first time by Benjamin Schenck in 1898, when he was a medical student at the Johns Hopkins Hospital in Baltimore. After isolation of the etiological agent, Schenck sent the sample to the mycologist Erwin Smith who concluded that the agent was a microorganism of the genus Sporotrichum. In 1900, the disease was reported for the second time by Hektoen and Perkins who classified the etiological agent as Sporothrix schenckii, with the pathogen being isolated from a specimen aspirated from the cutaneous lesions of the patient (Hektoen and Perkins 1900). In Europe, the first case was described in 1903 and more than 200 cases were reported over the following 10 years (Mariat 1968). The first case of sporotrichosis in Brazil was reported in 1907 by Lutz and Splendore, who also found that it was possible to culture the yeast form in vitro (Lutz and Splendore 1907). The dimorphic transition of this fungus was described by Howard (1961). Sporothrix schenckii is therefore a dimorphic pathogenic fungus and the etiological agent of human and animal sporotrichosis. The fungus belongs to the subdivision Deuteromycotina, class Hyphomycetes (Kwon-Chung and Bennett 1992). According to Mariat (1971) and Taylor (1970), the fungus Ceratiocys-
*Ophiostoma stenoceras* presents a conidial stage similar to that of *S. schenckii*; however, no conclusions exist regarding the description of the teleomorphic phase of this species (Travassos and Lloyd 1980). Other investigators have recently postulated that *O. stenoceras* may correspond to the teleomorph of *S. schenckii* (Lacaz et al. 2002, Beer et al. 2003). Previous studies based on DNA hybridization experiments, however, provided strong evidence that *O. stenoceras* is not the teleomorph of *S. schenckii* (Lacaz et al. 1998, Rodriguez-Del Valle et al. 1983, Alsina and Rodriguez-Del Valle 1984); however, temperature is a determining factor in dimorphism.

**BIOCHEMICAL ASPECTS OF THE* S. schenckii* SURFACE**

The cell wall is the surface envelope of the fungal cell and plays a central role in pathogen-host interaction, thus mediating various processes associated with the pathogenesis of these microorganisms. The cell wall of *S. schenckii* consists of alkali-soluble and -insoluble glucans found in both morphological phases of this fungus. Alkali-soluble glucans of the yeast form of *S. schenckii* are linked by $\beta(1,3)$, $\beta(1,6)$ and $\beta(1,4)$ bonds at 44, 28 and 28%, respectively. Insoluble glucans contain 66, 29 and 5% of $\beta(1,3)$, $\beta(1,6)$ and $\beta(1,4)$ bonds. No variations in $\beta$-glucan composition have been observed with the morphological transition of *S. schenckii* (Previero et al. 1979).

The presence of melanin in the cell wall may have a protective role in this pathogen since this pigment functions as a scavenger of free radicals (Romero-Martinez et al. 2000, Morris-Jones et al. 2003).

A glycoprotein fraction containing 33.5% rhamnose, 57% mannose and 14.2% protein, called peptidorhamnomannan, was isolated from the cell wall of the yeast phase of *S. schenckii* (Lloyd and Bitoon 1971). In parallel, a glycoconjugate containing rhamnose and mannose was detected in a frac-
tion isolated from the culture filtrate of *S. schenckii* (Ishizaki 1970). The peptidorhamnomannan glycopeptide fraction reacted with sera from patients with sporotrichosis and with concanavalin A (Con A) (Lloyd and Biton 1971, Travassos et al. 1977). Besides, this fraction inhibited the adhesion of this fungus to extracellular matrix proteins, suggesting the presence of adhesins on the surface of this pathogen (Lima et al. 2001, 2004). In addition to rhamnose and mannose, polysaccharides containing galactose have also been identified on the surface of this fungus, suggesting the presence of a galactomannan (Mendonça et al. 1976, Mendonça-Previato et al. 1980). A peptidorhamnogalactan was obtained by extraction from yeast-like cells with deoxycholate and subsequent chromatography on a DEAE-Sephadex column (Nakamura 1976). Structural studies on the rhamnomannan fraction obtained by extraction with 2% KOH at 100°C showed the presence of mono- and dirhamnolside side chains bound to a main chain of $\alpha 1\rightarrow 6$ linked mannosyl residues (Travassos et al. 1973, 1974). Glucuronic acid residues have also been described in an acidic fraction of rhamnomannans from *S. schenckii* (Gorin et al. 1977).

The reactivity of the *S. schenckii* cell wall with ConA has been observed by electron microscopy in both mycelial and yeast phases of this fungus (Travassos et al. 1977). Immunocytochemical analysis of antigens in the outermost layer of yeast cells of *S. schenckii* revealed labeling of these antigens by polyclonal antibodies co-localized with regions reactive with ConA (Castillo et al. 1990). Although containing antigenic epitopes, however, the rhamnomannan chains described thus far did not contain ConA-binding ligands in their structure (Lloyd and Travassos 1975, Lloyd et al. 1978). Whereas rhamnomannans showed no reactivity with ConA in double diffusion precipitation tests, the glycopeptide fraction (peptidorhamnomannan) reacted with this lectin (Travassos et al. 1977). Oligosaccharide chains O-linked to peptidorhamnomannan containing up to 5 monosaccharide units were subsequently characterized, revealing the presence of $\alpha$-D-mannose, $\alpha$-D-glucuronic acid and $\alpha$-L-rhamnose residues (Lopes-Alves et al. 1992). The presence of 2-O-substituted $\alpha$-D-mannopyranoside units in these oligosaccharides and of terminal nonreducing mannose residues in the O-linked disaccharide explains the reactivity of the fungal cell wall with ConA (Lopes-Alves et al. 1992). In addition, O-glycoside chains showed important antigenic determinants involving $\alpha$-D-glucuronic acid residues mono- and disubstituted by terminal nonreducing rhamnose residues (Figure 1) (Lopes-Alves et al. 1994).

**EPIDEMIOLOGY**

Sporotrichosis has been mainly reported in tropical and temperate zones (Conti-Diaz 1980, Fukushiro 1984, Itoh et al. 1986, Itoh et al. 1986, Kwong-Chung and Bennett 1992, Eisfelder et al. 1993, Chakrabarti et al. 1994, Vismar and Hull 1997, Pappas et al. 2000, Espinosa-Texis et al. 2001, Barros et al. 2004, Schubach et al. 2004). In the south of the American continent the disease more frequently occurs in the humid autumn or in summer (Mackinnon et al. 1969, Lopes et al. 1999), whereas in Mexico the highest incidence is observed in cold and dry seasons (González-Ochoa 1965). No seasonal difference, however, has been reported by other authors (Vismar and Hull 1997, Lyon et al. 2003, Barros et al. 2004).

Sporotrichosis can affect all ages (Rippon 1988, Vismar and Hull 1997) and the number of cases involving men and women varies from region to region (González-Ochoa 1965, Muir and Pritchard 1984, Itoh et al. 1986, Rippon 1988, Barros et al. 2004). In some regions, the difference in the distribution of cases according to age and gender might be explained by the type of fungal exposure (Fukushiro 1984, Kusuhara et al. 1988, Lyon et al. 2003), but no association has been found in other regions (Pappas et al. 2000).

Generally, infection results from inoculation of the fungus through thorns, splinters, scratches and small traumas during leisure and occupational ac-
Fig. 1 – Structure of O-glycosidic-linked tetra- and pentasaccharides of S. schenckii cell wall peptido-rhamnomannans showing the main epitopes and the Con A binding residues (adapted from Lopes-Alves et al. 1992).

Sporotrichosis usually occurs in isolated cases or in small family or professional outbreaks. Epidemics are rare and, if present, have been related to a single source of infection (Campos et al. 1994, Bustamante and Campos 2001). The largest epidemic so far reported occurred in South Africa, with about 3000 gold miners being infected with the fungus which occurred in the wood girders of the mine structure (Quintal 2000). Another epidemic burst affected 84 workers who participated in reforestation programs in 15 states of the United States and was associated with the sphagnum moss used to store the seedlings originating from Pennsylvania (CDC 1988).

Human sporotrichosis has been sporadically related to the scratch or bite of animals (Moore and Davis 1918, Kauffman 1999). However, the presence of the fungus in the mouth or nails of the animals was not demonstrated in any of the cases described (Moore and Davis 1918, Fischman et al. 1973). Since the 1980s, domestic cats have gained importance in the transmission of the mycosis to man (Read and Sperling 1982, Dunstan et al. 1986a, b, Larsson et al. 1989, Reed et al. 1993, Werner and Werner 1994, Schubach and Schubach 2000).

The largest epidemic of sporotrichosis due to zoonotic transmission was described in Rio de Janeiro (Barros et al. 2001). Between 1998 and 2004, only at the Evandro Chagas Clinical Research Institute, Fiocruz, 1503 cats, 64 dogs and 759 humans (Figure 2) have been diagnosed by isolation of S. schenckii in culture (Barros et al. 2004, Schubach et al. 2004, 2006). As a rule, feline disease preceded human and canine diseases, and the individuals most frequently affected included housewives taking care of cats with sporotrichosis (Barros et al. 2004). Domiciliary or professional contact with sick cats was observed in 84.1% of the canine cases and in 84.7% of the human cases. Among the latter, 57.1% reported a history of a scratch or bite.

To investigate the potential of cats as a pos-
sible source of infection, 148 cats with sporotrichosis and 84 apparently healthy cats in domiciliary contact with the affected animals were studied regarding the presence of *S. schenckii* in different biological materials. The fungus was isolated from 100% of cutaneous lesions, 47 (n = 71, 66.2%) nasal cavity swabs, 33 (n = 79, 41.8%) oral cavity swabs, and 15 (n = 38, 39.5%) pools of nail fragments from cats with sporotrichosis. *Sporothrix schenckii* was also isolated from oral swabs of three (n = 84, 3.57%) apparently healthy cats in domiciliary contact with the affected animals (Schubach et al. 2002). Isolation of the fungus from the nails and oral cavities of cats reinforces evidence indicating that transmission can occur through a scratch or bite, whereas isolation from nasal fossae and cutaneous lesions, together with the wealth of yeast-like elements observed in histological sections of skin biopsies (Schubach et al. 2003b, 2004), demonstrates the possibility of contamination through secretions (Rosser and Dunstan 1998, Kauffman 1999, Schubach et al. 2004). The results of molecular typing of *S. schenckii* isolated from humans and animals support this hypothesis (Reis R, personal communication).

**CLINICAL MANIFESTATIONS**

Sporotrichosis has diverse clinical manifestations and investigators disagree regarding the clinical classification of the disease (Lacaz et al. 2002). Below is a schematic presentation of the clinical classification that we consider best from a practical point of view:

<table>
<thead>
<tr>
<th><strong>Cutaneous</strong></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Lymphocutaneous</td>
<td></td>
</tr>
<tr>
<td>Fixed</td>
<td></td>
</tr>
<tr>
<td>Disseminated or multiple</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th><strong>Mucosa</strong></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Ocular</td>
<td></td>
</tr>
<tr>
<td>Nasal</td>
<td></td>
</tr>
<tr>
<td>Others</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th><strong>Extracutaneous</strong></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Pulmonary</td>
<td></td>
</tr>
<tr>
<td>Osteoarticular</td>
<td></td>
</tr>
<tr>
<td>Meningeal</td>
<td></td>
</tr>
<tr>
<td>Generalized</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th><strong>Residual (Sequela)</strong></th>
<th></th>
</tr>
</thead>
</table>

<table>
<thead>
<tr>
<th><strong>Special Forms</strong></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Spontaneous regression</td>
<td></td>
</tr>
<tr>
<td>Hypersensitivity</td>
<td>(erythema nodosum,</td>
</tr>
<tr>
<td></td>
<td>erythema multiforme)</td>
</tr>
</tbody>
</table>

The most frequent clinical form (about 80%) is the lymphocutaneous form. It starts with a nodular or ulcerated lesion at the site of fungal inoculation and follows a regional lymphatic trajectory characterized by nodular lesions that ulcerate, fistulate and heal, representing true gummae. This clinical description led to naming the disease as ‘ascending nodular lymphangitis’. In general, the fixed cutaneous form is characterized by infiltrated nodular, ulcerated or erythematousquamous lesions located on exposed areas where fungal inoculation occurred (Figure 3A). The disseminated cutaneous forms have mainly been observed among immunosuppressed patients, especially HIV-positive individuals (Donabedian et al. 1994, Shaw et al 1989).

Mucosal involvement is not common but may occur, and preferentially affects the ocular mucosa (Figure 4) (Vieira Dias et al. 1997).

Among the extracutaneous forms, osteoarticular and pulmonary involvement are the most com-
Fig. 3 – Fixed cutaneous form exhibiting a nodular lesion on the face of a child; (A) before treatment and (B) after treatment. The patient was diagnosed by a serological test with the SsCBF antigen.

Fig. 4 – Ulcerated granulomatous lesion draining purulent discharge affecting the ocular conjunctiva and surrounding skin in an adolescent girl.
mon, but there are reports of cases of severe hematogenic dissemination with involvement of multiple organs.

In places with a large number of cases of the disease, reports of spontaneous regression are not rare, nor are the occurrence of hypersensitivity reactions such as erythema nodosum/multiforme (experience of the authors of the present work). Usually, lesions located in the deep dermis or subcutaneous tissue result in skin scars.


Women patients predominated (n = 122, 68%) and the age-range was 5 to 89 years old, with a median of 39 years. Among a group of 178 patients, 156 reported domiciliary or professional contact with cats with a suspected or confirmed diagnosis of sporotrichosis, and 97 reported a history of a scratch or bite. The most frequent occupations were domestic activities (30%) and students (18%). Five percent of the patients were veterinarians and veterinary assistants. The disease was frequent in women involved in domestic activities and animal care.

Histopathological examination of 73 biopsy fragments revealed a granulomatous infiltrate in 66 (90.4%) and the fungus was detected in 21 (28.8%), corresponding to a high frequency (Barros et al. 2004). The lymphocutaneous form was the most frequent clinical form (n = 95, 55.6%), followed by the fixed cutaneous form (n = 45, 25.3%) and multiple cutaneous lesions (n = 29, 16.3%) (Barros et al. 2003, 2004). Mucosal involvement was observed in five patients (2.8%), affecting the nasal cavity in one and the conjunctiva in four (Schubach et al. 2003a, Barros et al. 2004, Schubach et al. 2005). The lesions varied in morphology including nodules, tubercles, pustules, cysts, gummas, ulcers, ulcerovegetating lesions, verrucous lesions, and plaques accompanied or not by lymphangitis. The predominant sites affected were the upper limbs (65.2%), followed by the lower limbs (12.9%) and the face (6.2%) (Barros et al. 2004). Arthralgia was a symptom reported by 53 (29.8%) patients and five of them had signs of arthritis (Pereira et al. 2002, Barros et al. 2004). For the first time erythema nodosum (Gutierrez-Galhardo et al. 2002) and erythema multiforme (Gutierrez-Galhardo et al. 2005) were associated with sporotrichosis. These uncommon manifestations might be explained by different mechanisms, such as repeated inoculation during prolonged contact with sick animals, self-inoculation, dissemination of the fungus through the bloodstream, or aspiration of conidia and/or yeasts originating from lesion exudates or from respiratory particles released by sneezing infected cats (Schubach et al. 2002, Barros et al. 2003). Additionally, continuous exposure to large amounts of fungus contaminated materials and subclinical reinfections may result in hypersensitivity (Gutierrez-Galhardo et al. 2002).

Thirteen (7.3%) of the 178 patients showed spontaneous regression of the cutaneous lesions, whereas 165 (92.7%) required specific treatment with itraconazole administered orally at the dose of 100 mg/day for 4 to 36 weeks (median = 12 weeks). Of these 165 patients, 149 (90.3%) were cured and 16 (9.7%) abandoned treatment. Five of the nine diabetic patients required a longer time of treatment (16 to 24 weeks) and the itraconazole dose needed to be increased to 200-400 mg/day in three patients. Four other patients with chronic obstructive pulmonary disease and nine with a history of alcohol abuse responded well to treatment with 100 mg itraconazole/day. All patients were followed up for 6 months to one year after the end of treatment and many of them remained in contact with cats with sporotrichosis. Lesion reactivation was observed in only two patients, who were treated again and cured (Barros et al. 2004).

**DIFFERENTIAL DIAGNOSIS**

Due to the diversity of the clinical forms of sporotrichosis, there is also a vast set of differential diagnosis with other pathological conditions. Examples
include leishmaniasis, nocardiosis, chromomycosis, tuberculosis, rosacea, noninfectious granulomatous diseases, and psoriasis, among others.

*S. schenckii* ANTIGENS AND LABORATORY DIAGNOSIS

The role of *S. schenckii* glycopeptide antigens was reported for the first time by González-Ochoa and Figueroa (1947) in precipitation studies and intradermal skin tests using a preparation of antigens isolated from the culture filtrate, called sporotrichin, and antigens isolated from yeast cells. Antigens isolated from both the culture filtrate and the cell wall had been used for intradermal tests in guinea pigs and humans (Nielsen-Jr 1968). Sporotrichin tests, however, have yielded false-positive results in subjects without a history of sporotrichosis (Schneidau et al. 1964). Antigens isolated from the culture filtrate are highly heterogeneous and the positive reactions in intradermal tests and the antigen reactivity in immunodiffusion tests depend on the culture conditions (Takata and Ishizaki 1983).

Intradermal skin tests using sporotrichin as antigen are useful in epidemiological studies and as an auxiliary method in the detection of atypical forms of the disease. As mentioned earlier, however, the intradermal sporotrichin test is not routinely used for the diagnosis of sporotrichosis because it can yield false-positive and false-negative results (Toriello et al. 1991). In 1984, Albornoz et al. proposed the use of immunodiffusion and immunoelectrophoresis tests in the diagnosis of sporotrichosis using a fungal culture filtrate as antigen, in assays employing sera from patients with the disseminated cutaneous form.

The characterization of easily standardized, specific antigens has expanded the possibility of using serological methods as a fast and noninvasive diagnostic tool in systemic mycoses. These methods are mainly used in cases of extracutaneous sporotrichosis or of atypical forms, permitting the selection of an adequate treatment regimen (Scott et al. 1987, Bernardes-Engemann et al. 2005).

Since the cell wall is the surface structure of the fungal cell and therefore mediates the relationship with the host, it represents an important source of antigens. Several studies have been conducted with the objective to isolate and identify antigens on the cell wall of *S. schenckii*. Epitopes consisting of mono- and dirhamnoside side chains are present in the N-linked chains of the peptidorhamnomannan (Travassos 1989), but cross-react with *Streptococcus* spp. (Nakamura et al. 1977) and *Klebsiella pneumoniae* K47 (Ishizaki et al. 1979).

Subsequent studies have demonstrated that some O-glycosidic chains, mainly O-linked tetra- and pentasaccharides, carry important antigenic epitopes, $\alpha$-L-Rhap 1→2 $\alpha$-D-GlcA p and $\alpha$-L-Rhap 1→4 $\alpha$-D-GlcA p, which have not been described in other species (Lopes-Alves et al. 1994). Using the reactivity of these O-glycosidic chains against ConA, Lima and Lopes-Bezerra (1997) isolated two subfractions from the peptidorhamnomannan fraction, one of them binding and the other unable to bind to ConA. The ConA-binding fraction, called 3sCBF, was specifically recognized by sera from patients with the cutaneous form of sporotrichosis, with the reaction being significantly inhibited by O-linked tetra- and pentasaccharides (Penha and Lopes-Bezerra 2000). This was the first report on a cell wall antigen, purified from *S. schenckii* infective phase, that could potentially be applied in the serodiagnosis of sporotrichosis with good sensitivity.

As mentioned, other important carbohydrate epitopes of the yeast phase of *S. schenckii* bearing non-reducing rhamnose end units (Rhap $\alpha$ 1→3 Man p) had been described on the cell wall rhamnomannans (reviewed by Travassos 1989). We had shown that this N-linked epitope is also present in the O-linked trisaccharide (Rhap $\alpha$ 1→3 Man p $\alpha$ 1→2 Man p) which is expressed in both morphological phases of *S. schenckii*. This oligosaccharide, however, could only inhibit in 28% (Table I) the precipitation reaction of the peptidorhamnomannan with a rabbit anti-*S. schenckii* serum (Lopes-Alves et al. 1994). On the other hand, when the O-linked trisaccharide was assayed together with the O-linked pentasaccharide the inhibition reached 95% (Table I). Further-
more, these results were reproduced in inhibition assays with patients’ sera demonstrating the presence of IgG antibodies in human sera against the α-L-Rhap 1→4 [α-L-Rhap 1→2] α-D-GlcAβ epitope (Penha and Lopes-Bezerra 2000). To our knowledge, the presence of α-D-GlcAβ units 2,4 disubstituted by rhamnose units has not been described so far in other species.

### TABLE I

<table>
<thead>
<tr>
<th>Oligosaccharide</th>
<th>% Inhibition</th>
</tr>
</thead>
<tbody>
<tr>
<td>Trisaccharide</td>
<td>28</td>
</tr>
<tr>
<td>Tetrasccharide</td>
<td>63</td>
</tr>
<tr>
<td>Pentasaccharide</td>
<td>82</td>
</tr>
<tr>
<td>Tri + pentasaccharide</td>
<td>95</td>
</tr>
</tbody>
</table>

*Adapted from Lopes-Alves et al. (1994).*

Based on these observations, an ELISA test was developed that showed 90% sensitivity and 86% overall efficacy when tested against sera obtained from 92 patients with the lymphocutaneous, fixed cutaneous, disseminated cutaneous or multiple and extracutaneous forms of sporotrichosis, in addition to 117 control serum samples obtained from healthy individuals or subjects with other diseases (Bernardes-Engemann et al. 2005). This diagnostic tool seems to be useful not only to promptly diagnose disseminated and atypical forms of this disease but also for those unresolved cases that are negative by the classical mycological test. An example of this condition is the patient shown in Figure 3. The patient was suspected of having fixed cutaneous sporotrichosis but the mycological test gave successive negative results. Several therapeutic regimens were tried without success. After a positive serological result with the SsCBF antigen this patient received the appropriate antifungal therapy which resulted in healing of the lesion (Figure 3B). Recently, we have applied the ELISA test to detect IgG antibodies in other clinical materials such as the synovial fluid and the cerebrospinal fluid (CSF) from two patients with meningeal sporotrichosis and osteoarticular sporotrichosis, respectively. In parallel, we had performed the ELISA test using a mannanprotein fraction (MP) from *Saccharomyces cerevisiae* as a control. As shown in Figures 5 and 6, we could detect significant levels of anti-SsCBF antibodies in both body fluids. Later on, sporotrichosis was confirmed by the isolation of *S. schenckii*.

This serological test has also been useful for the therapeutic follow-up of patients (Bernardes-Engemann et al. 2005).

### TREATMENT

Different drug regimens are used for the treatment of sporotrichosis, including potassium iodide, itraconazole, terbinafine, fluconazole and amphotericin B. The choice is based on the individual’s clinical condition, the extent of the cutaneous lesions, assessment of drug interactions and adverse events, and systemic involvement.

Potassium iodide (KI) was the first drug successfully used in the treatment of sporotrichosis. It is formulated as a saturated solution containing approximately 142 g potassium iodide in 100 mL water. Treatment is initiated with five drops administered three times a day, and the dose is increased by one drop/dose/day until reaching a total of 4-6 g/day (25-30 drops, three times a day). *Indications:* localized forms (lymphocutaneous, fixed cutaneous or mucosal forms). Potassium iodide is not recommended during pregnancy (category D). *Main adverse events:* nausea, metallic taste, hypothyroidism, iododerma, and iodism (Sterling and Heymann 2000, Lesher et al. 1994).

Itraconazole is administered orally at the dose of 100 to 400 mg/day. *Indications:* the same as described for potassium iodide but the drug is also used for immunosuppressed patients with more extensive clinical forms and systemic involvement. The drug is not indicated during pregnancy.
Fig. 5 – Serological follow-up of a patient with meningeal sporotrichosis by the ELISA test with the SsCBF antigen. Cerebrospinal fluid (CSF) samples were collected in a 18-month period and tested at 1:400 dilution. The presence of cross-reacting IgGs was evaluated with an irrelevant mannoprotein (MP). The black arrows indicate, respectively, a disease recurrence episode and a period of discontinuation of amphotericin B due to its toxic side effects.

Fig. 6 – Detection of IgG antibodies against the SsCBF antigen in the synovial fluid sample from a patient with osteoarticular sporotrichosis but without exhibiting skin lesions. The synovial fluid was serially diluted (1:2) and assayed either against SsCBF or a mannoprotein from S. cerevisae (MP).
Main adverse events: gastrointestinal events such as nausea, vomiting and diarrhea, headache, abdominal pain, hypersensitivity reactions, and liver dysfunction. Drug interactions: interactions with other drugs are numerous, increasing or reducing the action of the antifungal agent or of the concomitantly administered drug, and depend for its activity on enzymes of the cytochrome P-450 system. It is necessary to consult tables and the manufacturer recommendations as well as to evaluate the risks and benefits of drug use (Bolao et al. 1994, Tay et al. 1997).

Terbinafine is not formally indicated for the treatment of sporotrichosis but reports have shown therapeutic success. The present authors have experience with the use of this drug, which has the same indication of itraconazole, is fungicidal, classified as category B for pregnancy. Terbinafine is administered orally at the dose of 250 to 500 mg/day (Hull and Vismer 1992). Main adverse events: gastrointestinal events, headache, taste disturbance, and neutropenia. Drug interactions are also observed but are fewer than those reported for itraconazole.

Reports on the successful treatment with fluconazole are found in the literature, but this is not a first choice drug. Fluconazole is administered orally at 200 to 400 mg/day, but can also be applied intravenously in more severe cases. It also depends on the cytochrome P-450 enzymatic system and is a pregnancy category C drug.

Amphotericin B is indicated for the treatment of moderate to severe clinical forms in immunosuppressed individuals and those who did not respond to the drugs described above. Amphotericin B is a pregnancy category B drug and is nephrotoxic and cardiotoxic. The drug is administered intravenously, with a maximum daily dose of 50 mg and a total cumulative dose of 500 to 1000 mg. Depending on the severity of the disease, the patient may later use another drug administered orally (Kauffman 1995).

The duration of treatment until clinical cure is 6 to 8 weeks, on average, in immunocompetent patients.

**PROGNOSIS**

The prognosis of sporotrichosis is generally good even in immunosuppressed patients, although its outcome may in a few cases be incapacitating or even fatal.

**ACKNOWLEDGMENTS**

L.M.L.B and A.S. are fellowships from the Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq). We are grateful to Dr. Luiz R. Travassos for the careful revision and suggestions to improve this manuscript.

**RESUMO**

Durante muito tempo a esporotricose foi descrita como uma doença de baixa incidência no Brasil, no entanto, relatos recentes mostram que não só o número de casos descritos vem aumentando como a incidência de formas clínicas mais graves ou atípicas da doença vem ocorrendo com maior frequência. Dados recentes apontam que este grupo clínico já constitui cerca de 10% dos casos de esporotricose com diagnóstico confirmado. Apresentações clínicas mais raras, principalmente a esporotricose osteoarticular, podem estar associadas tanto a quadros de imunodepressão do paciente quanto à transmissão zoonótica desta doença. O diagnóstico da forma extracutânea ou de formas atípicas é um desafio que tem como ferramenta auxiliar o desenvolvimento recente de um teste sorológico para o diagnóstico das diferentes formas clínicas da esporotricose.

Palavras-chave: esporotricose, diagnóstico, epidemiologia, terapêutica, parede celular, antígenos.

**REFERENCES**


An Acad Bras Cienc (2006) 78 (2)


LLOYD KO, MENDONÇA-PREVIAO L AND TRAVERSOSS LR. 1978. Distribution of antigenic polysaccharides in different cell types of Sporothrix schenckii.
as studied by immunofluorescence staining with rabbit antisera. Exp Mycol 2: 130–137.


TRAVASSOS LR. 1985. Sporothrix schenckii. In: SNAUSZLO PJ (Ed), Dimorphism, with emphasis on


